Evidence map›Paper›PMID 35933297›Full record

ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2022

Epidemiology, risk factors, and outcomes of lung retransplantation: An analysis of the International Society for Heart and Lung Transplantation Thoracic Transplant Registry.

Michael O Harhay, Wida S Cherikh, Alice E Toll, Jason D Christie, Josef Stehlik, Daniel Chambers, Don Hayes, Edward Cantu

Open access · greenAbstract read
In one paragraph

Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Impact of pre-transplant veno-venous extracorporeal membrane oxygenation on post-lung transplant infections.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Characteristics and Outcomes of 1500 Lung Transplantations in the Leuven Lung Transplant Program: Turning Past Lessons Into Tomorrow's Foundations.Transplant international : official journal of the European Society for Organ Transplantation · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Michael O HarhayDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Palliative and Advanced Illness Research (PAIR) Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Pulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; International Society for Heart and Lung Transplantation - International Thoracic Organ Transplant Registry, Dallas, Texas. Electronic address: mharhay@pennmedicine.upenn.edu.
Wida S CherikhInternational Society for Heart and Lung Transplantation - International Thoracic Organ Transplant Registry, Dallas, Texas; United Network for Organ Sharing (UNOS), Richmond, Virginia.
Alice E TollUnited Network for Organ Sharing (UNOS), Richmond, Virginia.
Jason D ChristiePulmonary, Allergy and Critical Care Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Josef StehlikInternational Society for Heart and Lung Transplantation - International Thoracic Organ Transplant Registry, Dallas, Texas; Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, Utah.
Daniel ChambersInternational Society for Heart and Lung Transplantation - International Thoracic Organ Transplant Registry, Dallas, Texas; School of Clinical Medicine, The University of Queensland, Brisbane, Australia.
Don HayesInternational Society for Heart and Lung Transplantation - International Thoracic Organ Transplant Registry, Dallas, Texas; Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Edward CantuDivision of Cardiovascular Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
International Society for Heart and Lung Transplantation · USUniversity of Pennsylvania · USCincinnati Children's Hospital Medical Center · USThe University of Queensland · AUUniversity of Utah · US

Funding

Objective Lung Assessment Tools for Improved Organ Use in Lung TransplantationR01HL155821 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI CANTU, EDWARD · 2021 to 2025
$3.0M
NHLBI NIH HHS R01 HL155821
6 · The paper itself

Abstract

backgroundLung retransplantation is a complex surgical decision that represents the only potential treatment option for recipients suffering from lung allograft failure. We sought to describe the modern landscape of lung retransplantation and to compare the relative importance of selected clinical, donor, and recipient factors on mortality in the year following lung retransplantation.

methodsWe conducted a retrospective cohort study of first-time adult recipients of deceased donor lung retransplants reported to the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Transplant Registry from May 2005 through June 2017. In addition to describing the characteristics of lung retransplant recipients, we examined 1 year survival overall, and by initial transplant-retransplant procedure type, recipient age, retransplant indication, and time-to-lung retransplantation (i.e., inter-transplant interval). We used the Somers' D

resultsOur cohort included 1,597 lung retransplant recipients. 2005 was the first year with more than 100 retransplants, and since 2007, 138 to 188 retransplants (approximately 4%-6% of all transplants) were reported annually to the ISHLT Registry. The median inter-transplant interval was 3.4 years (interquartile range: 1.6-6.2 years). Forty-three percent of the cohort had an obliterative bronchiolitis retransplant indication, whereas 17% had primary graft failure. One-third (32%) were retransplanted within 2 years of their primary transplant, and 64% received a double lung transplant both times, whereas 36% received consecutive single lung transplants. Six-month and 1 year survival (82% and 76%) were higher for double-double lung retransplant recipients than for single-single recipients (76% and 69%). The 3 strongest prognostic factors for 1 year mortality were the inter-transplant interval (decreasing hazard with longer intervals), donor age (increasing hazard with older age), and need for mechanical ventilation preceding lung retransplantation.

conclusionsRetransplants comprise approximately 5% of annual lung transplants worldwide. The factor most strongly associated with 1 year mortality in this population was the duration of time since the primary lung transplant, with a persistent reduction in risk as more time elapses.

Indexed as

Heart TransplantationLung TransplantationRespiratory InsufficiencyAdultGraft SurvivalHumansLungRegistriesReoperationRetrospective StudiesRisk Factorsallograft failureend-stage lung diseaseepidemiologylung transplantretransplantation

Identifiers

PMID35933297
PMCPMC9986966
OpenAlexW4284700933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.